UT-MD Anderson Cancer Center: CD19-Targeted CAR NK Cell Therapy Achieves Promising One-Year Results in Patients With B-Cell Malignancies
January 19, 2024
January 19, 2024
HOUSTON, Texas, Jan. 19 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
Researchers identify key characteristics of donated cord blood units associated with strong clinical responses in Phase I/II trial
* * *
Researchers from The University of Texas MD Anderson Cancer Center reported promising results in a Phase I/II trial of 37 patients with relapsed or refractory B-cell malignancie . . .
* * *
Researchers identify key characteristics of donated cord blood units associated with strong clinical responses in Phase I/II trial
* * *
Researchers from The University of Texas MD Anderson Cancer Center reported promising results in a Phase I/II trial of 37 patients with relapsed or refractory B-cell malignancie . . .